New Modified Citrus Pectin Study: Oxaliplatin Synergy via Antioxidant Mechanisms

As independent, third party research on the original and patented form of Modified Citrus Pectin (MCP) continues to gain momentum, our understanding of MCP’s broad spectrum of benefits likewise expands with new indications, unique mechanisms, and clinically relevant applications. New research published earlier this year in Life Sciences adds to this growing body of knowledge, bringing the number of peer-reviewed publications on this form of MCP to 100+ studies—highlighting the remarkable ability of this natural solution to optimize clinical outcomes for key areas of health.

One area where MCP continues to excel is its proven synergy with a wide range of compounds, including powerful conventional oncology protocols. 

Oxaliplatin remains a cornerstone of chemotherapy for gastric cancer (GC), yet its clinical potential is often undermined by a dose-limiting side effect: chemotherapy-induced peripheral neuropathy (CIPN). Up to 95% of GC patients undergoing treatment develop CIPN, marked by numbness, tingling, neuropathic pain, and motor impairment, frequently forcing dose reductions or discontinuation of treatment. Despite its efficacy, the lack of clinical strategies to prevent or mitigate CIPN represents a significant challenge in GC as well as other cancer treatment protocols.

New Study: MCP Targets SOD3 to Improve Oxaliplatin and Reduce CIPN

The recent preclinical study published in Life Sciences (1) reveals a novel mechanism by which MCP selectively enhances extracellular superoxide dismutase (SOD3). This new study adds to the current body of data demonstrating MCP’s powerful synergistic potential, and expands our understanding of MCP as an antioxidant beyond its well-established role as a Galectin-3 inhibitor in oncology nutritional support and other critical areas of health (2).

Study Highlights

Targeted Antioxidant Action: Prior research shows MCP increases antioxidant defenses such as glutathione activity. This new study demonstrates MCP specifically upregulates antioxidant enzyme SOD3 without impacting SOD1 or SOD2.

SOD3’s Unique Role: This study shows SOD3 suppresses progression by modulating the SOD3/EGFR/PKP3/DSC2 signaling axis, rebalancing redox status and inhibiting abnormal cell growth, invasion, and migration.

Multiple Clinical Benefits: MCP’s activation of SOD3 reduced ROS production, suppressed abnormal  growth, and alleviated CIPN in mouse models. MCP enhanced the efficacy of oxaliplatin, allowing for lower doses. 

Oxaliplatin + MCP: Enhanced Efficacy with Reduced Toxicity

Prior research has demonstrated the synergistic efficacy of combining MCP with various conventional protocols . Consistent with those findings, this new study showed that when combined with MCP, low-dose oxaliplatin achieved clinical efficacy equivalent to high-dose oxaliplatin, without the associated CIPN severity. MCP’s modulation of SOD3 provided a protective effect against oxaliplatin-induced oxidative stress, offering a promising integrative strategy to improve outcomes while supporting quality of life. 

As third-party research on MCP continues to expand, stay tuned for additional highlights on the vast potential of this powerhouse ingredient to improve clinical protocols, reduce toxic side effects, and enhance patient outcomes—safely and naturally.  

References:

  1. Sun, C., et al. (2025). MCP-enhanced SOD3 activity inhibits…potentiates chemotherapy via modulating EGFR signaling. Life Sciences, 362, 123358. https://doi.org/10.1016/j.lfs.2024.123358

  2. Eliaz, I., & Raz, A. (2019). Pleiotropic effects of modified citrus pectin. Nutrients, 11(11), 2619.

Back to blog